Cost analysis of Down syndrome screening in advanced maternal age

Journal of Maternal-Fetal and Neonatal Medicine

Volumn 13, Issue 2, 2003, Pages 80-84

  Hartnett, J ^a   Borgida, A F ^a   Benn, P A ^a   Feldman, D M ^a   DeRoche, M E ^a   Egan, J F X ^b  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^b SAINT FRANCIS HOSPITAL AND MEDICAL CENTER   (United States)

Author keywords

Amniocentesis; Down syndrome screening; Genetic sonogram; Serum screen

Indexed keywords

ADULT; AMNIOCENTESIS; ARTICLE; BLOOD SAMPLING; COST BENEFIT ANALYSIS; DATA ANALYSIS; DIAGNOSTIC PROCEDURE; DOWN SYNDROME; ECHOGRAPHY; FEMALE; FETUS WASTAGE; GENETIC SCREENING; GESTATIONAL AGE; HUMAN; MAJOR CLINICAL STUDY; MASS SCREENING; MATERNAL AGE; MATERNAL SERUM; PREGNANCY; PRIORITY JOURNAL; SIGNAL DETECTION;

EID: 0037328588     PISSN: 14767058     EISSN: None     Source Type: Journal    
DOI: 10.1080/jmf.13.2.80.84     Document Type: Article

References (17)

1. Wald N, Leck I. Antenatal and Neonatal Screening, 2nd edn. London: Oxford University Press, 2000:85-8
2. Penrose LS. The relative effects of paternal and maternal age in mongolism. J Genet 1933;27:219
3. Cuckle HS, Wald NJ, Lindenbaum RH. Maternal serum alpha-fetoprotein measurement: a screening test for Down syndrome. Lancet 1984;1:926-9
4. Haddow JE, Palomaki GE, Knight GJ, et al. Prenatal screening for Down's syndrome with use of maternal serum markers. N Engl J Med 1992;327:588-93
5. Cheng EY, Luthy DA, Zebelman AM, et al. A prospective evaluation of a second-trimester screening test for fetal Down syndrome using maternal serum alpha-fetoprotein, hCG, and unconjugated estriol. Obstet Gynecol 1993;81:72-7
6. Egan JFX, Malakh L, Turner GW, et al. Role of ultrasound for Down syndrome screening in advanced maternal age. Am J Obstet Gynecol 2001;185:1028-31
7. Haddow JE, Palomaki GE, Knight GJ, et al. Reducing the need for amniocentesis in women 35 years of age or older with serum markers for screening. N Engl J Med 1994;330:1114-18
8. NIH Consensus Development Conferences. Antenatal diagnosis: amniocentesis. Clin Pediatr 1979;18:454-62
9. Egan JFX, Benn P, Borgida AF, et al. Efficacy of screening for fetal Down syndrome in the United States from 1974 to 1997. Obstet Gynecol 2000;96:979-85
10. Beazoglou T, Heffley D, Kyriopoulos J, et al. Economic evaluation of prenatal screening for Down syndrome in the U.S.A. Prenat Diagn 1998;18:1241-52
11. Vintzileos AM, Ananth CV, Smulian JC, et al. Cost-benefit analysis of prenatal diagnosis for Down syndrome using the British or the American approach. Obstet Gynecol 2000;95:577-83
12. Egan JFX, Kaminsky L, Deroche M, et al. Antenatal screening for Down syndrome in the US in 2001: a survey of maternal-fetal medicine specialists. Am J Obstet Gynecol 2002;187:1230-4
13. American College of Obstetricians and Gynecologists. Prenatal Diagnosis of Fetal Chromosomal Abnormalities. Practice Bulletin No. 27. ACOG, 2001
14. Caruso TM, Westgate MN, Holmes LB. Impact of prenatal screening on the birth status of fetuses with Down syndrome at an urban hospital, 1972-1994. Genet Med 1998;1:22-8
15. Bromley B, Leiberman E, Shipp TD, et al. The genetic sonogram: a method of risk assessment for Down syndrome in the second trimester. J Ultrasound Med 2002;21:1087-96
16. Nyberg DA, Souter VL, El-Bastawissi A, et al. Isolated sonographic markers for detection of fetal Down syndrome in the second trimester. J Ultrasound Med 2001;20:1053-63
17. Vintzileos AM, Campbell WA, Rodis JF, et al. The use of second trimester genetic sonogram in guiding clinical management of patients at increased risk for trisomy 21. Obstet Gynecol 1996;87:948-52